Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

situximab

- PMLiVE

Merck & Co’s anacetrapib data fails to generate much excitement

Treatment proves unable to reduce a composite outcome of major atherosclerotic events

UK Life Sciences Strategy - one year on

EMA starts firming up its stance on personalised medicines

But draft guidelines won't be ready much before 2019

- PMLiVE

Lynparza approval sets up tighter bout with PARP rivals

US regulator gives AZ the go-ahead for a new maintenance indication and formulation

- PMLiVE

Biotecnol taps into Cancer Research UK network for first trial

New drug hoped to have broad activity across multiple tumour types

- PMLiVE

How to keep your name development on schedule after the recent EMA NRG announcement

Three key action points

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

AstraZeneca AZ

Shock for AZ as MYSTIC trial stumbles at first hurdle

Combination fails to improve progression-free survival for lung cancer patients

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

- PMLiVE

Amgen aspires to new Kyprolis label in the US and Europe

Appeals to regulators to add survival data to multiple myeloma drug's labelling

- PMLiVE

FDA halts third Merck myeloma trial after patient deaths

More patients died on Keytruda combination than those on other treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links